Application of levofloxacin or pharmaceutically acceptable salt thereof in preparation of anti-cerebral ischemia-reperfusion injury medicine or health product

A technology of cerebral ischemia-reperfusion and levofloxacin, which is applied in application, drug combination, drug delivery, etc., can solve the problems that the effects of drugs or health care products on cerebral ischemia-reperfusion injury have not been reported, and achieve the protection of blood-brain barrier function , reduce the volume of cerebral infarction, and improve the effect of neurological dysfunction

Active Publication Date: 2022-03-08
SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Levofloxacin was patented in 1987 and approved for clinical use by the US FDA in 1996 (the patent expired in 2011). Its chemical structural formula is as follows: However, its role in the preparation of anti-cerebral ischemia-reperfusion injury medicines or health products has not been reported yet

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of levofloxacin or pharmaceutically acceptable salt thereof in preparation of anti-cerebral ischemia-reperfusion injury medicine or health product
  • Application of levofloxacin or pharmaceutically acceptable salt thereof in preparation of anti-cerebral ischemia-reperfusion injury medicine or health product
  • Application of levofloxacin or pharmaceutically acceptable salt thereof in preparation of anti-cerebral ischemia-reperfusion injury medicine or health product

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0022] 【Experimental Example 1】Effect of levofloxacin on neurological dysfunction in mice with cerebral ischemia-reperfusion injury

[0023] 1. The preparation process and drug treatment of the mouse cerebral ischemia-reperfusion injury (Ischemia-reperfusion injury, I / R injury) model.

[0024] C57BL / 6 male mice aged 8-10 weeks and weighing 20-30 g were randomly divided into three groups, namely solvent control group, levofloxacin 20 mg / kg administration group, and levofloxacin 60 mg / kg administration group. The above three groups used the suture method to establish the transient middle cerebral artery embolism-reperfusion model in mice. Mice were first anesthetized by isoflurane gas anesthesia (2.5% volume percent induction, 1.5% volume percent maintenance). After 5 min of anesthesia, the mice were fixed on the operating board in a supine position. Then use curved scissors to cut off the mouse hair on the neck of the mouse, and disinfect the neck of the mouse with sufficient...

experiment example 2

[0030] [Experimental Example 2] Effect of Levofloxacin on Cerebral Infarction Volume in Mice with Cerebral Ischemia-Reperfusion Injury

[0031]After behavioral testing, the mice were anesthetized and sacrificed by decapitation, and the whole brains were quickly frozen at -40°C and sectioned. The first incision is at the midpoint of the connecting line between the anterior pole and the optic chiasm; the second incision is in the optic chiasm; the third incision is in the funnel handle; the fourth incision is between the funnel handle and the caudal pole of the posterior lobe, and the thickness of each piece is 2mm. . Brain tissue slices were incubated with 0.5% (mass volume percent) 2,3,5-triphenyltetrazolium chloride (TTC) solution at 37°C for 15 minutes, then replaced with 4% (mass volume percent) paraformaldehyde for 20 minutes . Finally, place the first slice to the fourth slice from top to bottom and take pictures of the slices, such as figure 2 As shown in A. During ...

experiment example 3

[0034] 【Experimental Example 3】Effect of levofloxacin on the integrity of the blood-brain barrier in mice with cerebral ischemia-reperfusion injury

[0035] After the behavioral test, 2% (mass volume percentage) Evans blue (5ml / kg) was injected into each group through the tail vein 2 hours before execution, and 2 hours later, the heart was perfused with normal saline under isoflurane gas anesthesia, and the brain was quickly decapitated. , to take pictures of the whole brain. Whole brains were quickly frozen at -40°C and sectioned. The first incision is at the midpoint of the connecting line between the anterior pole and the optic chiasm; the second incision is in the optic chiasm; the third incision is in the funnel handle; the fourth incision is between the funnel handle and the caudal pole of the posterior lobe, and the thickness of each piece is 2mm. , and finally place the first slice to the fourth slice from top to bottom and take pictures of the slices, such as image...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of levofloxacin or a pharmaceutically acceptable salt thereof in the preparation of medicines or health care products for resisting cerebral ischemia-reperfusion injury. The present invention finds for the first time the application of levofloxacin or its pharmaceutically acceptable salt in the preparation of anti-cerebral ischemia-reperfusion injury medicine or health products, and levofloxacin or its pharmaceutically acceptable salt for anti-cerebral ischemia-reperfusion injury can reduce the Cerebral infarction volume, improve neurological dysfunction, and protect blood-brain barrier function are drugs suitable for the recovery period of stroke prognosis.

Description

technical field [0001] The invention belongs to the technical field of drugs for treating cardiovascular and cerebrovascular diseases, and in particular relates to the application of levofloxacin or a pharmaceutically acceptable salt thereof in the preparation of drugs or health care products against cerebral ischemia-reperfusion injury. Background technique [0002] Stroke, also known as stroke or cerebrovascular accident, is a disease in which brain tissue is damaged due to blockage or rupture of blood vessels in the brain that prevents blood from flowing into the brain. With the aging population in my country and the prevalence of unhealthy living habits, stroke has become the first cause of death and disability in adults in my country, and it is also one of the main causes of death and disability in the world. In my country, there are an average of 2.7 million new stroke cases every year, of which 50% of stroke patients have varying degrees of hemiplegia, 30% of patients...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/5383A61P9/10A61P25/00A23L33/10
CPCA61K31/5383A61K9/0019A61K9/0053A61P9/10A61P25/00A23L33/10A23V2002/00A23V2200/30A23V2200/326A23V2200/322
Inventor 畅君雷杨时伦马寅仲朱亚东
Owner SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap